HOME > TOP STORIES
TOP STORIES
-
REGULATORY Welireg, Airwin, Talvey and More Set for NHI Listing; Premiums Wiped Out by “Zero” Rule
August 7, 2025
-
REGULATORY DPO Floats Premium Expansion, Relaxed Criteria towards FY2026 Reform
August 7, 2025
-
REGULATORY Chuikyo Rules Out Long-Term Care Costs in Leqembi CEA, Confirms Price Cut
August 7, 2025
-
REGULATORY Wegovy, Leqvio, Phozevel to Face CEA-Linked Price Cuts in November
August 7, 2025
-
REGULATORY MHLW Device Review Chief Pledges Evidence-Based Approvals amid Diversifying Technologies
August 6, 2025
-
REGULATORY MHLW Trial Office Head Vows to Make Japan a Preferred Site for Clinical Studies
August 5, 2025
-
REGULATORY Wage-Based Price Premiums on Drugs Not an Option, Says MHLW Insurance Chief
August 4, 2025
-
BUSINESS Nihon Chouzai to Go Private through Tender Offer Backed by Advantage Partners
August 1, 2025
-
ORGANIZATION Japan Society Poised to Set Out Criteria to Standardize Regional Formularies, Eyes August Release
July 31, 2025
-
REGULATORY MHLW to Link GS1 and YJ Codes in Public Database, Launch Planned for FY2028
July 30, 2025
-
BUSINESS Gene Therapy Deaths Spur Strategic Rethink among Biotechs, Merck Exec Notes Investor Caution
July 30, 2025
-
REGULATORY Post-Marketing Oversight and Regulatory Reviews Must Work as One, Says New MHLW Safety Chief
July 29, 2025
-
REGULATORY Astellas Employee Did Not Appeal, Prison Sentence Finalized in China
July 29, 2025
-
COMMENTARY Pharmaceutical Policy at a Crossroad amid Political Upheaval in Japan
July 28, 2025
-
REGULATORY MSD’s 21-Valent Pneumococcal Shot Nears Japan Approval; Male Use of Silgard 9 Cleared
July 25, 2025
-
BUSINESS Chugai to Defer Domestic Supply of Elevidys amid Safety Review
July 25, 2025
-
REGULATORY Santen’s Glaucoma Drug, Taisho’s Insomnia Med Up for Panel Review on July 31
July 25, 2025
-
REGULATORY MHLW Plans to Ease Clinical Trial Ad Rules, Eyes Notification by March-End
July 24, 2025
-
BUSINESS Towa Launches Task Force to Tackle Nitrosamine Impurities, Share Solutions with Peers
July 24, 2025
-
REGULATORY New MHLW Drug Review Chief Aims to Dispel “Barrier” Perception, Pledges Active Engagement with Industry
July 23, 2025
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
